Home › Compare › APETF vs ABBV
APETF yields 718.80% · ABBV yields 3.06%● Live data
📍 APETF pulled ahead of the other in Year 1
Combined, APETF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of APETF + ABBV for your $10,000?
AlphaGen Intelligence Corp. operates as a game and software development company in North America and internationally. It holds a portfolio of assets in gaming, generative AI, technology, and content production services. The company owns and operates Shape, a metaverse studio, which builds the future of web3 gaming experiences and supporting companies as their metaverse partner to design and build leading brand and virtual retail experiences; MANA, a white-label SaaS solution that allows brands and other organizations to launch their own gaming platforms without having to fund technological or backend systems; and GamerzArena, a gaming platform that provides an esports ecosystem for all gamers that provides video game contests where gamers can compete for cash and prizes in leadership and bracket formats. AlphaGen Intelligence Corp. has a strategic partnership with XCAVE Studios Inc. to develop next-generation branded experiences in Fortnite. The company was formerly known as Alpha Metaverse Technologies Inc. and changed its name to AlphaGen Intelligence Corp. in June 2023. The company was incorporated in 2019 and is based in Vancouver, Canada.
Full APETF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.